Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Gains from Sales and Divestitures (2024 - 2026)

Sagimet Biosciences' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $63508.0 for Q1 2026.

  • Quarterly Gains from Sales and Divestitures changed N/A to $63508.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $63508.0 through Mar 2026, changed N/A year-over-year, with the annual reading at $281462.0 for FY2025, 0.0% changed from the prior year.
  • Gains from Sales and Divestitures came in at $63508.0 for Q1 2026, down from $281462.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $281462.0 in Q3 2025 to a low of $63508.0 in Q1 2026.
  • The 3-year median for Gains from Sales and Divestitures is $281458.0 (2024), against an average of $237869.6.
  • The largest YoY upside for Gains from Sales and Divestitures was 0.0% in 2025 against a maximum downside of 0.0% in 2025.
  • Sagimet Biosciences' Gains from Sales and Divestitures stood at $281458.0 in 2024, then grew by 0.0% to $281462.0 in 2025, then tumbled by 77.44% to $63508.0 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Gains from Sales and Divestitures are $63508.0 (Q1 2026), $281462.0 (Q4 2025), and $281462.0 (Q3 2025).